

1
2
3 **Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung**
4 **disease in the SENSCIS trial**
5
6

7
8 Elizabeth R. Volkman,^{1*} Michael Kreuter,^{2*} Anna M. Hoffmann-Vold,³ Marlies Wijzenbeek,⁴
9
10 Vanessa Smith,⁵ Dinesh Khanna,⁶ Christopher P. Denton,⁷ Wim A. Wuyts,⁸ Corinna Miede,⁹
11
12 Margarida Alves,¹⁰ Steven Sambevski,¹⁰ Yannick Allanore,¹¹ on behalf of the SENSCIS trial
13
14 investigators
15

16
17 ¹Department of Medicine, Division of Rheumatology, University of California, David Geffen
18
19 School of Medicine, Los Angeles, CA, USA; ²Center for Interstitial and Rare Lung Diseases,
20
21 Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member
22
23 of the German Center for Lung Research, Heidelberg, Germany; ³Department of
24
25 Rheumatology, Oslo University Hospital, Oslo, Norway; ⁴Department of Respiratory
26
27 Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands;
28
29 ⁵Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent,
30
31 Belgium; ⁶Department of Medicine, University of Michigan, Ann Arbor, MI, USA; ⁷University
32
33 College London Division of Medicine, Centre for Rheumatology and Connective Tissue
34
35 Diseases, London, UK; ⁸Unit for Interstitial Lung Diseases, Department of Pulmonary
36
37 Medicine, University Hospitals Leuven, Leuven, Belgium; ⁹mainanalytics GmbH, Sulzbach
38
39 (Taunus), Germany; ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein,
40
41 Germany; ¹¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital,
42
43 Paris, France.
44

45
46
47 *Contributed equally.
48
49

50
51
52 **Corresponding author:**
53

54
55 Elizabeth R. Volkman, University of California, David Geffen School of Medicine, Los
56
57 Angeles, CA, USA.
58

59
60 Email: EVolkman@mednet.ucla.edu

Abstract

Objective: To investigate the rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough or dyspnoea in the SENSICIS trial.

Methods: Patients in the SENSICIS trial were randomized to receive nintedanib or placebo. Subgroups with and without cough or dyspnoea at baseline were defined by responses to the St. George's Respiratory Questionnaire.

Results: At baseline, 114/575 patients (19.8%) did not have cough and 172/574 patients (30.0%) did not have dyspnoea. In the placebo group, the rate of FVC decline over 52 weeks was similar in patients with and without cough (-95.6 and -83.4 mL/year, respectively) or dyspnoea (-95.8 and -87.7 mL/year, respectively). The effect of nintedanib versus placebo on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough (difference: 74.4 [95% CI -11.1, 159.8] versus 31.5 [-11.1, 74.1]) and without than with dyspnoea (79.8 [9.8, 149.7] versus 25.7 [-19.9, 71.3]), but interaction p-values did not indicate heterogeneity in the treatment effect between these subgroups ($p=0.38$ and $p=0.20$, respectively).

Conclusion: In the placebo group of the SENSICIS trial, the rate of FVC decline was similar irrespective of the presence of cough or dyspnoea at baseline. The effect of nintedanib on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough or dyspnoea at baseline, but no statistically significant heterogeneity was observed between the subgroups.

Trial registration: ClinicalTrials.gov, <https://clinicaltrials.gov>, NCT02597933

Keywords: nintedanib; connective tissue diseases; vital capacity; scleroderma, systemic

Key messages:

- The SENSCIS trial enrolled patients with systemic sclerosis-associated interstitial lung disease regardless of respiratory symptoms.
- The rate of forced vital capacity (FVC) decline was similar irrespective of cough or dyspnoea.
- The effect of nintedanib on FVC decline was similar irrespective of cough or dyspnoea.

Introduction

Systemic sclerosis (SSc) is a rare and heterogeneous autoimmune disease characterized by immune dysregulation, microvascular damage and progressive fibrosis of the skin and internal organs [1]. Interstitial lung disease (ILD) is the leading cause of death in patients with SSc [2]. Dyspnoea and cough are common in patients with SSc-ILD [3-7] and have a negative impact on patients' quality of life [4,8-10]. Cough in patients with SSc-ILD may be due to the SSc-ILD itself [4-6], to gastroesophageal reflux disease (GERD) [11,12], to other comorbidities [13], or to medication use [14]. Similarly, dyspnoea is a common manifestation of ILD, but may also occur due to comorbidities such as pulmonary hypertension or cardiac involvement [15,16].

The severity and timing of onset of cough and dyspnoea in patients with SSc-ILD are variable. Many patients do not report symptoms even when ILD is evident on high-resolution computed tomography (HRCT) and their lung function is impaired [7,17-19]. This may be due in part to patients with SSc-ILD reducing activities that require exertion, or to limitations in the questionnaires used to assess respiratory symptoms.

1
2
3 The SENSCIS trial enrolled patients with and without respiratory symptoms, in contrast to
4 Scleroderma Lung Studies I and II, which only enrolled patients with respiratory symptoms.
5 In the SENSCIS trial, the rate of decline in forced vital capacity (FVC) (mL/year) over 52
6 weeks was reduced by 44% in patients randomized to nintedanib compared to placebo [20].
7 Furthermore, nintedanib reduced the risk of an absolute decline in FVC $\geq 10\%$ predicted or
8 death over 52 weeks [21].
9
10
11
12
13
14
15

16 While there is some evidence that the presence of cough or dyspnoea may be associated
17 with the progression of ILDs [22-25], the relationships between cough and dyspnoea and the
18 course of SSc-ILD have not been established. The purpose of the present analyses was to
19 assess the rate of FVC decline, and the effect of nintedanib on the rate of FVC decline, in
20 patients with and without cough and dyspnoea at baseline in the SENSCIS trial.
21
22
23
24
25
26
27
28
29

30 **Material and methods**

31 **Trial design**

32
33 The design of the SENSCIS trial (NCT02597933) has been published, together with the trial
34 protocol [20]. Briefly, eligible patients had SSc with onset of first non-Raynaud symptom ≤ 7
35 years before screening, extent of fibrotic ILD $\geq 10\%$ on HRCT (based on assessment of the
36 whole lung), FVC $\geq 40\%$ predicted, and diffusion capacity of the lung for carbon monoxide
37 (DLco) 30–89% predicted. Patients on prednisone ≤ 10 mg/day or equivalent and/or stable
38 therapy with mycophenolate or methotrexate for ≥ 6 months were allowed to participate.
39 Patients were randomized 1:1 to receive nintedanib or placebo stratified by the presence of
40 anti-topoisomerase I antibody (ATA). Patients remained on blinded treatment until the last
41 patient had reached week 52 but for ≤ 100 weeks. The trial was carried out in compliance
42 with the principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for
43 Good Clinical Practice of the International Conference on Harmonisation. The trial was
44 performed at 194 sites in 32 countries and was approved by an independent ethics
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 committee or institutional review board at every site. The sites are listed in Section A of the
4 supplementary appendix to the primary manuscript on the trial results [20]. Patients provided
5 written informed consent before trial entry.
6
7
8
9

10 11 12 **Analyses**

13
14
15 In *post-hoc* analyses, we analyzed the efficacy and safety of nintedanib in subgroups of
16 patients with and without cough at baseline and with and without dyspnoea at baseline
17 based on patients' answers to the questions in the St. George's Respiratory Questionnaire
18 (SGRQ) [26]. Patients who ticked boxes for "most days a week", "several days a week" or "a
19 few days a month" (rather than "only with chest infection" or "not at all") in response to the
20 question "Over the last month, I have coughed..." were considered to have cough. Patients
21 who ticked these boxes in response to the question "Over the last month, I have had
22 shortness of breath...." were considered to have dyspnoea.
23
24
25
26
27
28
29
30
31

32 We assessed the following outcomes in the nintedanib and placebo groups in subgroups
33 with and without cough and with and without dyspnoea: rate of decline in FVC (mL/year)
34 over 52 weeks; proportion of patients with absolute decline in FVC >5% predicted and >10%
35 predicted at week 52; proportion of patients with relative decline in FVC >5% predicted and
36 >10% predicted at week 52; time to absolute decline in FVC \geq 10% predicted or death over
37 52 weeks; absolute change from baseline in SGRQ total score at week 52; proportion of
38 patients with an absolute increase (worsening) in SGRQ total score of \geq 4 points at week 52.
39 An increase in SGRQ total score of \geq 4 points has been suggested to represent a meaningful
40 change in patients with idiopathic pulmonary fibrosis [27]. We also assessed the rate of
41 decline in FVC over 52 weeks in subgroups with both cough and dyspnoea, either cough
42 only or dyspnoea only, and neither cough nor dyspnoea at baseline.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 The rate of decline in FVC (mL/year) over 52 weeks was analysed using a random
57 coefficient regression model (with random slopes and intercepts) with fixed categorical
58
59
60

1
2
3 effects of ATA status and sex, fixed continuous effects of baseline FVC (mL), age, and
4 height and including baseline-by-time, treatment-by-subgroup and
5 treatment-by-subgroup-by-time interaction terms. The analysis was based on all
6 measurements taken over 52 weeks, including those from patients who discontinued trial
7 medication, in patients who had a baseline and ≥ 1 post-baseline FVC measurement. The
8 proportions of patients with absolute/relative declines in FVC $>5\%$ or $>10\%$ predicted and
9 with an increase in SGRQ total score of ≥ 4 points at week 52 were compared between
10 subgroups using a logistic regression model included terms for treatment, ATA status,
11 subgroup and treatment-by-subgroup interaction. Odds ratios were estimated for the effect
12 of treatment within each subgroup. Missing values were imputed using a worst value carried
13 forward approach.
14
15
16
17
18
19
20
21
22
23
24
25
26

27 The time to absolute decline in FVC $\geq 10\%$ predicted or death over 52 weeks was analysed
28 using a Cox proportional hazards model stratified by ATA status with terms for treatment,
29 subgroup and treatment-by-subgroup interaction. Absolute change from baseline in SGRQ
30 total score at week 52 were based on a mixed model for repeated measures (MMRM), with
31 fixed categorical effects of ATA status, treatment-by-subgroup-by-visit interaction and a
32 fixed continuous covariate of baseline SGRQ total score-by-visit interaction. For all
33 analyses, an interaction test was applied to assess potential heterogeneity in the effect of
34 nintedanib between the subgroups, with no adjustment for multiple testing. Adverse events
35 were coded according to preferred terms in the Medical Dictionary for Regulatory Activities
36 (MedDRA) and are presented descriptively.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Results

52 Patients

53
54 Of 575 patients with information on cough and 574 patients with information on dyspnoea,
55 114 patients (19.8%) did not have cough and 172 patients (30.0%) did not have dyspnoea at
56
57
58
59
60

1
2
3 baseline. Of 574 patients with information on both symptoms, 353 patients (61.5%) had both
4 cough and dyspnoea, 156 patients (27.2%) had cough only or dyspnoea only, and 65
5 patients (11.3%) had neither cough nor dyspnoea. Of the patients with cough, 353 (76.6%)
6 reported cough most or several days a week and 108 (23.4%) reported cough a few days a
7 month. Of the patients who reported dyspnoea, 283 (70.4%) reported dyspnoea most or
8 several days a week and 119 (29.6%) reported dyspnoea a few days a month.

9
10
11 At baseline, in patients with and without cough, respectively, the mean (SD) extent of fibrotic
12 ILD on HRCT was 37.2 (21.3)% and 30.7 (20.3)%, mean (SD) FVC was 71.5 (16.1) and 76.7
13 (18.3) % predicted, mean (SD) high-sensitivity C-reactive protein was 5.6 (9.7) and 9.6
14 (29.2) mg/L, 66.6% and 46.5% had gastroesophageal reflux disease, 80.3% and 77.2%
15 were taking drugs for gastric acid-related disorders, 50.1% and 49.1% were taking
16 corticosteroids, 48.4% and 49.1% of patients were taking mycophenolate, and 8.7% and
17 6.1% were taking ACE inhibitors (Table 1). Among the patients who reported cough on their
18 baseline SGRQ, 10.0% in the nintedanib group and 9.1% in the placebo group had cough
19 noted as a “baseline medical condition” by the investigator in the case report form completed
20 at screening; among patients who did not report cough on their baseline SGRQ, these
21 proportions were 5.2% and 1.8%, respectively.

22
23
24 At baseline, in patients with and without dyspnoea, respectively, the mean (SD) extent of
25 fibrotic ILD on HRCT was 37.7 (21.7)% and 31.6 (19.4)%, mean (SD) FVC was 71.0 (16.3)%
26 and 76.5 (16.8) % predicted, mean (SD) high-sensitivity C-reactive protein was 5.8 (10.3)
27 and 7.8 (24.3) mg/L, 68.9% and 47.7% had gastroesophageal reflux disease, 82.8% and
28 72.1% were taking drugs for gastric acid-related disorders, 53.5% and 41.9% were taking
29 corticosteroids, and 50.0% and 44.8% of patients were taking mycophenolate (Table 2).
30 Among the patients who reported dyspnoea on their baseline SGRQ, 13.4% in the
31 nintedanib group and 7.3% in the placebo group had dyspnoea noted as a “baseline medical
32 condition” by the investigator in the case report form completed at screening; among those
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 who did not report dyspnoea on their baseline SGRQ, these proportions were 5.1% and
4
5 3.2%, respectively.
6
7
8
9

10 **Outcomes in subgroups by cough at baseline**

11
12
13 In the placebo group, the rate of decline in FVC (mL/year) over 52 weeks was similar in
14
15 patients with and without cough at baseline (Figure 1A). The effect of nintedanib versus
16
17 placebo on reducing the rate of decline in FVC (mL/year) was numerically more pronounced
18
19 in patients without than with cough, but the exploratory interaction p-value did not indicate
20
21 heterogeneity in the treatment effect between these subgroups ($p=0.38$) (Figure 1A). The
22
23 proportions of patients with absolute/relative declines in FVC $>5\%$ or $>10\%$ predicted were
24
25 similar or lower in patients treated with nintedanib than placebo in patients with and without
26
27 cough at baseline, with no heterogeneity detected between the subgroups (Table 3).
28
29 Similarly, no heterogeneity was detected between these subgroups in the time to an
30
31 absolute decline in FVC $\geq 10\%$ or death ($p=0.33$) (Table 3).
32
33

34
35 Changes in SGRQ total score at week 52 were small in both the nintedanib and placebo
36
37 groups in both subgroups by cough at baseline. No heterogeneity was detected in the effect
38
39 of nintedanib on the absolute change in SGRQ total score between the subgroups by cough
40
41 (Table 3). The proportion of patients with an increase (worsening) in SGRQ total score of ≥ 4
42
43 points at week 52 was similar in patients treated with nintedanib and placebo both in patients
44
45 with and without cough, with no heterogeneity detected between the subgroups (Table 3).
46
47

48
49 The adverse event profile of nintedanib was similar in the subgroups by cough
50
51 (Supplementary Table S1, available at *Rheumatology* online). The proportions of patients
52
53 with adverse events that led to discontinuation of trial medication in the nintedanib and
54
55 placebo groups, respectively, were 15.7% and 6.5% in patients with cough at baseline and
56
57 17.2% and 17.9% in those without cough at baseline.
58
59
60

Outcomes in subgroups by dyspnoea at baseline

In the placebo group, the rate of decline in FVC was similar in patients with and without dyspnoea at baseline (Figure 1B). The effect of nintedanib versus placebo on reducing the rate of decline in FVC was numerically more pronounced in patients without than with dyspnoea, but the exploratory interaction p-value did not indicate heterogeneity in the treatment effect between these subgroups ($p=0.20$) (Figure 1B). The proportions of patients with absolute/relative declines in FVC $>5\%$ or $>10\%$ predicted were similar or lower in patients treated with nintedanib than placebo in patients with and without dyspnoea at baseline, with no heterogeneity detected between the subgroups (Table 4). Similarly, no heterogeneity was detected between these subgroups in the time to an absolute decline in FVC $\geq 10\%$ or death ($p=0.81$) (Table 4).

Changes in SGRQ total score at week 52 were small in both the nintedanib and placebo groups in both subgroups by dyspnoea at baseline. No heterogeneity was detected in the effect of nintedanib versus placebo on the absolute change in SGRQ total score between the subgroups (Table 4). The proportion of patients with an increase (worsening) in SGRQ total score of ≥ 4 points at week 52 was similar in patients treated with nintedanib and placebo both in patients with and without cough at baseline, with no heterogeneity detected between the subgroups (Table 4).

The adverse event profile of nintedanib was similar in the subgroups by dyspnoea (Supplementary Table S2, available at *Rheumatology* online). The proportions of patients with adverse events that led to discontinuation of trial medication in the nintedanib and placebo groups, respectively, were 17.7% and 7.8% in patients with dyspnoea at baseline and 11.5% and 10.6% in those without dyspnoea at baseline.

Outcomes in subgroups by cough and dyspnoea at baseline

In the placebo group, the rate of decline in FVC was similar in patients who had both cough and dyspnoea, cough only or dyspnoea only, or neither cough nor dyspnoea (Figure 1C).

The effect of nintedanib versus placebo on reducing the rate of decline in FVC was numerically more pronounced in patients with fewer or no symptoms, but the exploratory interaction p-value did not indicate heterogeneity in the treatment effect across subgroups ($p=0.14$).

Discussion

Our analyses demonstrated that patients with SSc-ILD enrolled in the SENSCIS trial who had cough or dyspnoea at baseline had a numerically greater extent of fibrotic ILD and numerically lower FVC % predicted and DLco % predicted at baseline than patients without these symptoms. Data from Scleroderma Lung Studies I and II, which enrolled patients with SSc-ILD and exertional dyspnoea based on Mahler's Dyspnoea Index, indicated that the presence of cough at baseline (based on a cough severity index or on responses to the questions about cough and phlegm in the SGRQ) was associated with lower DLco, worse dyspnoea and a greater extent of fibrosis on HRCT, but not with lower FVC [5,10]. It should be noted that in the SENSCIS trial, both the patients who did not have cough and the patients who did not have dyspnoea had a mean extent of fibrotic ILD (based on assessment of the whole lung) of over 30%. These findings highlight that respiratory symptoms may be a late presentation of SSc-ILD, at least in a subgroup of patients, and support the screening of all patients with SSc for ILD, irrespective of symptoms, as recommended by experts [28-30].

Among patients in the SENSCIS trial who reported cough or dyspnoea in response to the question in the SGRQ, only around 10% had that symptom recorded by the investigator. The reasons for this difference are unknown, but it is possible that the investigators did not ask

1
2
3 the patients explicit questions about these symptoms at screening. This observation
4 suggests that patient-reported outcomes measures such as the SGRQ may support
5 physicians in identifying patients with these symptoms in routine clinical practice.
6
7

8
9
10 In our analyses, no difference in the rate of loss of lung function over the following year was
11 detected between subgroups based on the presence of cough or dyspnoea at baseline. This
12 is consistent with an analysis of data from 535 patients with SSc-ILD in the EUSTAR
13 database, which found no significant difference in the 5-year decline in FVC between
14 patients with or without dyspnoea at baseline [31]. These findings highlight the importance of
15 regular monitoring of *all* patients with SSc-ILD for progression, not just those with severe or
16 symptomatic disease [28].
17
18

19
20
21 Compared with patients who received placebo, patients treated with nintedanib had a lower
22 rate of decline in FVC across the subgroups. Interestingly, we observed numerically greater
23 effects of nintedanib in the subgroups without dyspnoea and without cough, despite these
24 subgroups having less severe disease at baseline based on the extent of fibrotic ILD on
25 HRCT. These results suggest that the presence of cough or dyspnoea alone should not be
26 used as an indicator of when SSc-ILD is “severe” enough to warrant treatment. Experts in
27 the field have proposed that the initiation of treatment for SSc-ILD should be based on more
28 than one measure of disease severity (e.g. extent of fibrosis on HRCT, pulmonary function
29 tests, symptoms) as well as on other factors, including risk factors for progression and
30 patient preferences [28,30,32]. Prompt treatment of SSc-ILD may help to preserve lung
31 function and ultimately improve outcomes.
32
33

34
35
36 Consistent with previous studies [5,7], there was a high prevalence of cough (80%) and
37 dyspnoea (70%) in the SENSICIS trial. Managing symptoms and maintaining patients’ quality
38 of life should be part of a holistic approach to the care of patients with SSc-ILD [33].
39
40

41
42
43 However, alleviation of cough and dyspnoea in patients with ILD is challenging given the
44 lack of treatments with robust evidence of efficacy [6,34]. In Scleroderma Lung Study II,
45 patients with SSc-ILD and exertional dyspnoea who were treated with cyclophosphamide or
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 mycophenolate for 24 months experienced significant improvements in dyspnoea (based on
4 the Transitional Dyspnoea Index) and in SGRQ total score, but there was no placebo control
5 [35]. In the SENSCIS trial, there was no statistically significant effect of nintedanib on
6
7 change in SGRQ total score [20] and no heterogeneous effect of nintedanib on change in
8
9 SGRQ total score between patients with or without cough or dyspnoea at baseline was
10
11 detected.
12
13
14

15
16 Limitations of our analyses include that they were not powered for formal statistical testing of
17 the individual subgroups and the interaction p-values should be regarded as exploratory. Our
18 analyses were not adjusted for the presence of comorbidities such as GERD, pulmonary
19 hypertension, or cardiac involvement that may have an impact on respiratory symptoms or
20 the course of FVC decline, nor for the use of comedications. The presence of cough and
21 dyspnoea at baseline were based solely on responses to two questions in the SGRQ, which
22 have not been validated as a means of determining the presence of cough or dyspnoea in
23 patients with ILDs. We only investigated subgroups based on the presence of cough or
24 dyspnoea at baseline and did not consider whether development or resolution of cough
25 during the trial was associated with a different course of SSc-ILD.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 In conclusion, in patients with SSc-ILD in the SENSCIS trial, patients with cough or
42 dyspnoea at baseline had a numerically greater extent of fibrotic ILD and numerically lower
43 FVC % predicted than patients without dyspnoea or cough, but patients without cough or
44 dyspnoea also showed considerable fibrosis on HRCT and impairment in FVC. The rate of
45 decline in FVC in the placebo group was numerically similar irrespective of the presence of
46 cough or dyspnoea at baseline. The effect of nintedanib on reducing the rate of FVC decline
47 was numerically more pronounced in patients without than with cough or dyspnoea at
48 baseline, but no statistically significant heterogeneity was observed between these
49 subgroups. These data suggest that the presence of cough or dyspnoea alone should not be
50 used to inform when to initiate nintedanib in patients with SSc-ILD. More research is needed
51
52
53
54
55
56
57
58
59
60

1
2
3 to understand the underlying mechanisms and potential prognostic value of cough and
4
5 dyspnoea in patients with SSc-ILD.
6
7

8 **Acknowledgements:** We thank the patients who participated in the SENSISCIS trial. The
9
10 SENSISCIS trial was funded by Boehringer Ingelheim International GmbH (BI). The authors
11
12 meet criteria for authorship as recommended by the International Committee of Medical
13
14 Journal Editors (ICMJE). The authors did not receive payment for development of this
15
16 manuscript. Writing assistance was provided by Elizabeth Ng and Wendy Morris of
17
18 FleishmanHillard, London, UK, which was contracted and funded by BI. Support with
19
20 statistical programming was provided by Rafal Falkowski on behalf of BI. BI was given the
21
22 opportunity to review the manuscript for medical and scientific accuracy as well as
23
24 intellectual property considerations.
25
26
27
28
29
30

31 **Disclosure statement:** Elizabeth R. Volkmann reports grants from Forbius and Kadmon
32
33 and has served on advisory boards and received payment for lectures from BI. Michael
34
35 Kreuter reports grants, consulting fees and payment for presentations from BI and Roche; he
36
37 has a leadership or fiduciary role with the German Respiratory Society and Deutsche
38
39 gesellschaft für Pneumologix. Anna M. Hoffmann-Vold reports grants, consulting fees,
40
41 support for attending meetings, and payment for presentations from BI; consulting fees,
42
43 support for attending meetings and payment for presentations from Actelion, Medscape,
44
45 Roche; consulting fees and payment for presentations from Arxx Therapeutics, Bayer, Lilly,
46
47 Merck Sharp & Dohme; she has a leadership or fiduciary role with EUSTAR, the Nordic PH
48
49 vision group, and the Norwegian SSc study group. Marlies Wijsenbeek reports grants,
50
51 consulting fees, support for attending meetings and payment for presentations from BI and
52
53 Hoffmann-la Roche; grants from The Netherlands Organisation for Health Research and
54
55 Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Patient
56
57 Association, The Thorax Foundation, ErasmusMC and Sarcoidosis.nl; she has received
58
59
60

1
2
3 consulting fees and served on a Data Safety Monitoring Board or Advisory Board with
4 Galapagos; consulting fees from Bristol-Myers Squibb, Galecto, Respivot; payment for
5 presentations from Novartis; she has served on a Data Safety Monitoring Board or Advisory
6 Board with Savara; she is secretary of the Idiopathic Interstitial Pneumonia group of the
7 European Respiratory Society, member of the board of the Netherlands Respiratory Society,
8 member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and
9 Related Disorders Federation, chair of the educational committee of the European
10 Reference Network for Rare Lung Diseases, member of the advisory board of the Dutch lung
11 fibrosis and sarcoidosis patient associations. Vanessa Smith reports grants and speaker
12 fees from Janssen-Cilag; grants from the Belgian Fund for Scientific Research in Rheumatic
13 Diseases; research support from Research Foundation Flanders; research support,
14 consulting fees, support for attending meetings and speaker fees from BI; payment for
15 presentations from Accord Healthcare and UCB; support for attending meetings from
16 Celgene; she is chair of the EULAR study group on microcirculation in rheumatic diseases
17 and co-chair of the ACR study Group on microcirculation and the SCTC working group on
18 capillaroscopy. Dinesh Khanna reports grants and consultancy fees from Bristol-Myers
19 Squibb; grants, consulting fees and payment for presentations from Horizon Therapeutics;
20 grants from Pfizer; royalties or licenses from the University of California Los Angeles
21 Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0; consulting fees and
22 payment for presentations from AbbVie, Actelion, BI, CSL Behring, Genentech; consulting
23 fees from Talaris and Theraly; he has a leadership or fiduciary role and owns stock in Eicos
24 Sciences. Christopher P. Denton reports grants and consulting fees from CSL Behring,
25 GlaxoSmithKline, Inventiva; grants from Arxx Therapeutics and Servier; consulting fees and
26 payment for presentations from BI and Corbus; consulting fees from AbbVie, Acceleron
27 Pharma, Bayer, Horizon Therapeutics, Roche and Sanofi; and payment for presentations
28 from Janssen. Wim Wuyts reports grants from BI, Galapagos, Roche. Corinna Miede is an
29 employee of mainanalytics GmbH, Sulzbach (Taunus), Germany, which was contracted by
30 BI to assist with these analyses. Margarida Alves and Steven Sambevski are employees of
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 BI. Yannick Allanore has received consulting fees and payment for presentations from BI;
4 consulting fees from Sanofi; and has participated in a Data Safety Monitoring Board or
5 advisory board for BI, Chemomab, Curizon, Medsenic, Menarini, Sanofi.
6
7
8
9

10 **Funding:** This work was supported by Boehringer Ingelheim International GmbH (BI). The
11 authors did not receive payment for development of this manuscript.
12
13
14

15 **Data sharing:** See online supplementary material, available at *Rheumatology* online.
16
17
18
19
20

21 **References**


- 22 1. van den Hoogen F, Khanna D, Fransen J *et al.* 2013 classification criteria for systemic
23 sclerosis: an American College of Rheumatology/European League against
24 Rheumatism collaborative initiative. *Arthritis Rheum* 2013;65:2737-47.
25
26 2. Hoffmann-Vold AM, Fretheim H, Halse AK *et al.* Tracking impact of interstitial lung
27 disease in systemic sclerosis in a complete nationwide cohort. *Am J Respir Crit Care*
28 *Med* 2019;200:1258-66.
29
30 3. Faisal A, Alghamdi BJ, Ciavaglia CE *et al.* Common mechanisms of dyspnea in chronic
31 interstitial and obstructive lung disorders. *Am J Respir Crit Care Med* 2016;193:299-309.
32
33 4. Cheng JZ, Wilcox PG, Glaspole I *et al.* Cough is less common and less severe in
34 systemic sclerosis-associated interstitial lung disease compared to other fibrotic
35 interstitial lung diseases. *Respirology* 2017;22:1592-97.
36
37 5. Tashkin DP, Volkmann ER, Tseng CH *et al.* Improved cough and cough-specific quality
38 of life in patients treated for scleroderma-related interstitial lung disease: results of
39 Scleroderma Lung Study II. *Chest* 2017;151:813-20.
40
41 6. Biring SS, Kavanagh JE, Irwin RS *et al.* Treatment of interstitial lung disease
42 associated cough: CHEST guideline and expert panel report. *Chest* 2018;154:904-17.
43
44 7. Hu S, Hou Y, Wang Q *et al.* Prognostic profile of systemic sclerosis: analysis of the
45 clinical EUSTAR cohort in China. *Arthritis Res Ther* 2018;20:235.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 8. Khanna D, Clements PJ, Furst DE *et al*. Correlation of the degree of dyspnea with
4 health-related quality of life, functional abilities, and diffusing capacity for carbon
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Theodore AC, Tseng CH, Li N *et al*. Correlation of cough with disease activity and
treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from
the Scleroderma Lung Study. *Chest* 2012;142:614-21.
11. Kahrilas PJ, Altman KW, Chang AB *et al*. Chronic cough due to gastroesophageal reflux
in adults: CHEST guideline and expert panel report. *Chest* 2016;150:1341-60.
12. Li Q, Wallace L, Patnaik P, Alves M *et al*. Disease frequency, patient characteristics,
comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and
systemic sclerosis-associated interstitial lung disease: a US cohort study. *Rheumatology*
(Oxford). 2021;60:1915-25.
13. Irwin RS, French CL, Chang AB, Altman KW, CHEST Expert Cough Panel.
Classification of cough as a symptom in adults and management algorithms: CHEST
guideline and expert panel report. *Chest* 2018;153:196-209.
14. Shim J, Song W, Morice AH. Drug-induced cough. *Physiol Res* 2020;69(Suppl 1):S81-
92.
15. Vacca A, Meune C, Gordon J *et al*. Cardiac arrhythmias and conduction defects in
systemic sclerosis. *Rheumatology (Oxford)* 2014;53:1172-7.
16. Galiè N, Humbert M, Vachiery JL *et al*. 2015 ESC/ERS Guidelines for the diagnosis and
treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment
of pulmonary hypertension of the European Society of Cardiology (ESC) and the
European Respiratory Society (ERS): Endorsed by: Association for European Paediatric
and Congenital Cardiology (AEPC), International Society for Heart and Lung
Transplantation (ISHLT). *Eur Respir J* 2015;46:903-75.

17. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. *Arthritis Rheum* 1994;37:1283-9.
18. Adler S, Huscher D, Siegert E *et al.* Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. *Arthritis Res Ther* 2018;20:17.
19. Forestier A, Le Gouellec N, Béhal H *et al.* Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: description and prognosis factors. *Semin Arthritis Rheum* 2020;50:1406-13.
20. Distler O, Highland KB, Gahlemann M *et al.* Nintedanib for systemic sclerosis-associated interstitial lung disease. *N Engl J Med* 2019;380:2518-28.
21. Maher TM, Mayes MD, Kreuter M *et al.* *Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial.* *Arthritis Rheumatol* 2021;73:671-6.
22. Nishiyama O, Taniguchi H, Kondoh Y *et al.* A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. *Eur Respir J* 2010;36:1067-72.
23. du Bois RM, Weycker D, Albera C *et al.* Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011;184:459–66.
24. Ryerson CJ, Abbritti M, Ley B *et al.* Cough predicts prognosis in idiopathic pulmonary fibrosis. *Respirology* 2011;16:969-75.
25. Case AH, Hellkamp AS, Neely ML *et al.* Associations between patient-reported outcomes and death or lung transplant in idiopathic pulmonary fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry. *Ann Am Thorac Soc* 2020;17:699-705.
26. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. *Respir Med* 1991;85(Suppl B):25-31.


- 1
2
3 27. Swigris JJ, Wilson H, Esser D *et al*. Psychometric properties of the St George's
4
5 Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from
6
7 the INPULSIS trials. *BMJ Open Respir Res* 2018;5:e000278.
- 8
9 28. Hoffmann-Vold AM, Maher TM, Philpot EE *et al*. The identification and management of
10
11 interstitial lung disease in systemic sclerosis: evidence-based European consensus
12
13 statements. *Lancet Rheumatol* 2020;2:E71-83.
- 14
15 29. Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial
16
17 lung disease. *Lancet Respir Med* 2020;8:304-20.
- 18
19 30. Roofeh D, Lescoat A, Khanna D. Treatment for systemic sclerosis-associated interstitial
20
21 lung disease. *Curr Opin Rheumatol* 2021; 33: 240-8.
- 22
23 31. Hoffmann-Vold AM, Allanore Y, Alves M *et al*. Progressive interstitial lung disease in
24
25 patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR
26
27 database. *Ann Rheum Dis* 2021;80:219-27.
- 28
29 32. Volkmann ER. Natural history of systemic sclerosis–related interstitial lung disease: how
30
31 to identify a progressive fibrosing phenotype. *J Scleroderma Relat Disord*
32
33 2020;5(2S):31-40.
- 34
35 33. Hoffmann-Vold AM, Allanore Y, Bendstrup E *et al*. The need for a holistic approach for
36
37 SSc-ILD - achievements and ambiguity in a devastating disease. *Respir Res*
38
39 2020;21:197.
- 40
41 34. Parshall MB, Schwartzstein RM, Adams L *et al*. An official American Thoracic Society
42
43 Statement: update on the mechanisms, assessment, and management of dyspnea. *Am*
44
45 *J Respir Crit Care Med* 2012;185:435-52.
- 46
47 35. Volkmann ER, Tashkin DP, LeClair H *et al*. Treatment with mycophenolate and
48
49 cyclophosphamide leads to clinically meaningful improvements in patient-reported
50
51 outcomes in scleroderma lung disease: results of Scleroderma Lung Study II. *ACR*
52
53 *Open Rheumatol* 2020;2:362-70.
- 54
55
56
57
58
59
60

FIGURE 1. Rate of decline in FVC during SENSIS trial in subgroups by respiratory symptoms at baseline.




Treatment-by-time-by-subgroup interaction p=0.38

B



Treatment-by-time-by-subgroup interaction p=0.20

C



Treatment-by-time-by-subgroup interaction p=0.14

Legend: Rate of decline in FVC (mL/year) over 52 weeks in subgroups by (A) cough at baseline, (B) dyspnoea at baseline, and (C) both cough and dyspnoea, cough only or dyspnoea only, or neither cough nor dyspnoea. FVC, forced vital capacity.

TABLE 1. Baseline characteristics in subgroups by cough at baseline.

	Patients with cough*		Patients without cough*	
	Nintedanib (n=229)	Placebo (n=232)	Nintedanib (n=58)	Placebo (n=56)
Age (years)	54.8 (11.8)	53.5 (12.8)	53.8 (11.9)	52.6 (11.8)
Female	172 (75.1)	166 (71.6)	49 (84.5)	46 (82.1)
Years since onset of first non-Raynaud symptom	3.5 (1.6)	3.5 (1.8)	3.5 (1.6)	3.5 (1.8)
Diffuse cutaneous SSc	120 (52.4)	122 (52.6)	32 (55.2)	24 (42.9)
ATA positive	138 (60.3)	142 (61.2)	35 (60.3)	35 (62.5)
High-sensitivity C-reactive protein [†]	5.3 (8.9)	5.9 (10.6)	8.4 (19.5)	10.9 (36.9)
Extent of fibrotic ILD on HRCT [‡]	38.5 (21.8)	36.0 (20.7)	29.7 (20.1)	31.9 (20.7)
FVC (mL)	2443 (701)	2535 (839)	2511 (867)	2565 (714)

FVC % predicted	71.3 (15.8)	71.8 (16.4)	77.0 (19.6)	76.4 (17.1)
DLco % predicted ^{§¶}	51.8 (14.7)	53.1 (15.2)	57.5 (15.6)	53.5 (14.9)
SpO ₂ (%) [#]	97.6 (1.8)	97.5 (2.6)	97.7 (2.2)	97.6 (2.4)
mRSS ^{**}	11.6 (9.4)	10.7 (8.7)	10.1 (8.3)	11.6 (9.3)
SGRQ total score [#]	43.9 (18.8)	42.3 (20.3)	28.0 (20.7)	27.1 (19.4)
Phlegm ^{††}	154 (67.2)	152 (65.5)	7 (12.1)	13 (23.2)
Asthma ^{††}	12 (5.2)	8 (3.4)	2 (3.4)	0
Gastroesophageal reflux disease ^{§§}	158 (69.0)	149 (64.2)	27 (46.6)	26 (46.4)
Drugs for gastric acid-related disorders ^{¶¶}	183 (79.9)	187 (80.6)	45 (77.6)	43 (76.8)
Immunosuppressants ^{¶¶}	198 (86.5)	195 (84.1)	54 (93.1)	47 (83.9)
Corticosteroids ^{¶¶}	124 (54.1)	107 (46.1)	28 (48.3)	28 (50.0)
Inhaled corticosteroids ^{##}	34 (14.8)	30 (12.9)	5 (8.6)	4 (7.1)
Mycophenolate (mofetil or sodium)	109 (47.6)	114 (49.1)	30 (51.7)	26 (46.4)
ACE inhibitors ^{***}	22 (9.6)	18 (7.8)	3 (5.2)	4 (7.1)
Cough reported by investigator at screening ^{†††}	23 (10.0)	21 (9.1)	3 (5.2)	1 (1.8)

Data are n (%) or mean (SD). *Information on cough at baseline was missing for 1 patient in the nintedanib group. †Normal range: ≤4.99 mg/L; data missing for 45 patients. ‡Assessed in whole lung to nearest 5% by central review. Pure (non-fibrotic) ground glass opacity was not included. §Corrected for haemoglobin. ¶Data missing for 7 patients. #Data missing for 10 patients. **Data missing for 2 patients. ††Patients who ticked boxes for “most days a week”,

1
2
3 “several days a week” or “a few days a month” (rather than “only with chest infection” or “not at all”) to the question “Over the last month, I have brought up
4 phlegm...” were considered to have phlegm at baseline. ^{##}Based on preferred term in the Medical Dictionary for Regulatory Activities (MedDRA).
5
6 ^{§§}Oesophageal involvement (dysphagia, reflux) reported at screening. ^{¶¶}Customized drug grouping. ^{###}WHO Anatomical Therapeutic Chemical (ATC) codes for
7 “adrenergics, inhalants” and “other drugs for obstructive airway diseases, inhalants” within the customized drug grouping “corticosteroids”. ^{***}WHO ATC
8 codes for “ACE inhibitors, plain” and “ACE inhibitors, combinations” within the customized drug grouping “antihypertensives”. ^{†††}Based on MedDRA preferred
9 terms ‘cough’, ‘productive cough’ and ‘upper-airway cough syndrome’. ACE, angiotensin-converting enzyme; ATA, anti-topoisomerase 1 antibody; DLco,
10 diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; HRCT, high resolution computed tomography; ILD, interstitial lung disease;
11 mRSS, modified Rodnan skin score; SGRQ, St George’s Respiratory questionnaire; SSc, systemic sclerosis; SpO₂, oxygen saturation; UIP, usual interstitial
12 pneumonia.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

TABLE 2. Baseline characteristics in subgroups by dyspnoea at baseline.

	Patients with dyspnoea*		Patients without dyspnoea*	
	Nintedanib (n=209)	Placebo (n=193)	Nintedanib (n=78)	Placebo (n=94)
Age (years)	54.8 (12.0)	53.6 (12.7)	53.9 (11.2)	53.0 (12.5)
Female	159 (76.1)	137 (71.0)	62 (79.5)	74 (78.7)
Years since onset of first non-Raynaud symptom	3.4 (1.6)	3.5 (1.7)	3.6 (1.7)	3.4 (1.9)
Diffuse cutaneous SSc	113 (54.1)	95 (49.2)	39 (50.0)	50 (53.2)
ATA positive	132 (63.2)	113 (58.5)	41 (52.6)	63 (67.0)
C-reactive protein [†]	5.5 (9.4)	6.0 (11.2)	6.8 (16.8)	8.6 (29.4)
Extent of fibrotic ILD on HRCT [‡]	38.7 (21.8)	36.6 (21.6)	31.3 (20.8)	31.9 (18.3)
FVC (mL)	2395 (672)	2531 (829)	2623 (871)	2570 (790)
FVC % predicted	70.6 (16.1)	71.4 (16.6)	77.4 (17.5)	75.6 (16.1)
DLco % predicted ^{§¶}	50.9 (14.7)	50.9 (14.2)	58.4 (14.8)	58.2 (15.7)
SpO ₂ (%) [#]	97.6 (1.8)	97.6 (2.4)	97.6 (2.1)	97.3 (2.7)
mRSS ^{**}	11.3 (9.3)	10.5 (9.0)	11.4 (8.9)	11.7 (8.6)
SGRQ total score [#]	47.8 (16.9)	45.8 (18.7)	21.6 (15.4)	25.9 (18.8)

Asthma ^{††}	12 (5.7)	7 (3.6)	2 (2.6)	1 (1.1)
Gastroesophageal reflux disease ^{‡‡}	147 (70.3)	130 (67.4)	38 (48.7)	44 (46.8)
Drugs for gastric acid-related disorders ^{§§}	174 (83.3)	159 (82.4)	54 (69.2)	70 (74.5)
Immunosuppressants ^{§§}	185 (88.5)	167 (86.5)	67 (85.9)	74 (78.7)
Corticosteroids ^{§§}	121 (57.9)	94 (48.7)	31 (39.7)	41 (43.6)
Inhaled corticosteroids ^{¶¶}	36 (17.2)	28 (14.5)	3 (3.8)	6 (6.4)
Mycophenolate (mofetil or sodium)	102 (48.8)	99 (51.3)	37 (47.4)	40 (42.6)
ACE inhibitors ^{##}	17 (8.1)	11 (5.7)	8 (10.3)	11 (11.7)
Dyspnoea reported by investigator at screening ^{***}	28 (13.4)	14 (7.3)	4 (5.1)	3 (3.2)

Data are n (%) or mean (SD). *Information on dyspnoea at baseline was missing for 1 patient each in the nintedanib and placebo groups. †Normal range: ≤ 4.99 mg/L; data missing for 45 patients. ‡Assessed in whole lung to nearest 5% by central review. Pure (non-fibrotic) ground glass opacity was not included. §Corrected for haemoglobin. ¶Data missing for 7 patients. #Data missing for 10 patients. **Data missing for 2 patients. ††Based on preferred term in the Medical Dictionary for Regulatory Activities (MedDRA). ‡‡Oesophageal involvement (dysphagia, reflux) reported at screening. §§Customized drug grouping. ¶¶WHO Anatomical Therapeutic Chemical (ATC) codes for “adrenergics, inhalants” and “other drugs for obstructive airway diseases, inhalants” within the customized drug grouping “corticosteroids”. ##WHO ATC codes for “ACE inhibitors, plain” and “ACE inhibitors, combinations” within the customized drug grouping “antihypertensives”. ***Based on MedDRA preferred terms ‘dyspnoea’ and ‘dyspnoea exertional’. ACE, angiotensin-converting enzyme; ATA, anti-topoisomerase 1 antibody; DLco, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; HRCT, high resolution computed tomography;

1
2
3 ILD, interstitial lung disease; mRSS, modified Rodnan skin score; SGRQ, St George's Respiratory questionnaire; SSc, systemic sclerosis; SpO₂, oxygen
4
5 saturation; UIP, usual interstitial pneumonia.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

TABLE 3. Outcomes in subgroups by cough at baseline.

	Patients with cough		Patients without cough	
	Nintedanib (n=228)	Placebo (n=232)	Nintedanib (n=58)	Placebo (n=56)
Rate of decline in FVC (mL/year) over 52 weeks, adjusted rate (SE)	-64.1 (15.6)	-95.6 (15.1)	-9.0 (30.7)	-83.4 (30.8)
Difference (95% CI)	31.5 (-11.1, 74.1)		74.4 (-11.1, 159.8)	
Treatment-by-time-by-subgroup interaction	p=0.38			
Relative decline in FVC (mL) >5% at week 52, n (%)	80 (35.1)	100 (43.1)	15 (25.9)	25 (44.6)
Odds ratio (95% CI)	0.71 (0.49, 1.04)		0.43 (0.20, 0.95)	
Treatment-by-subgroup interaction	p=0.26			
Relative decline in FVC (mL) >10% at week 52, n (%)	41 (18.0)	42 (18.1)	7 (12.1)	10 (17.9)
Odds ratio (95% CI)	0.99 (0.62, 1.60)		0.63 (0.22, 1.81)	
Treatment-by-subgroup interaction	p=0.44			

Absolute decline in FVC >5% predicted at week 52, n (%)	49 (21.5)	65 (28.0)	10 (17.2)	17 (30.4)
Odds ratio (95% CI)	0.70 (0.46, 1.08)		0.48 (0.20, 1.17)	
Treatment-by-subgroup interaction	p=0.45			
Absolute decline in FVC >10% predicted at week 52, n (%)	17 (7.5)	19 (8.2)	3 (5.2)	5 (8.9)
Odds ratio (95% CI)	0.90 (0.46, 1.78)		0.55 (0.13, 2.44)	
Treatment-by-subgroup interaction	p=0.56			
Absolute decline in FVC ≥10% predicted or death at week 52, n (%)	34 (14.8)*	49 (21.1)	6 (10.3)	13 (23.2)
Hazard ratio (95% CI) [†]	0.71 (0.46, 1.10)		0.41 (0.16, 1.09)	
Treatment-by-subgroup interaction	p=0.33			
Absolute change from baseline in SGRQ total score at week 52, adjusted mean (SE) [‡]	0.2 (1.0)	-1.2 (1.0)	3.1 (2.0)	0.5 (2.1)
Difference (95% CI)	1.4 (-1.3, 4.1)		2.6 (-3.0, 8.1)	
Treatment-by-time-by-subgroup interaction	p=0.72			

Absolute increase from baseline in SGRQ total score of ≥ 4 points at week 52, n (%) [§]	87 (39.9)	72 (31.9)	24 (44.4)	21 (40.4)
Odds ratio (95% CI)	1.42 (0.96, 2.09)		1.18 (0.54, 2.55)	
Treatment-by-subgroup interaction	0.68			

*Analysed in 229 patients in the nintedanib group with cough at baseline. †Time-to-event analysis. ‡Analysed in 226 patients in the nintedanib group and 230 patients in the placebo group with cough at baseline, and 56 patients in the nintedanib group and 53 patients in the placebo group without cough at baseline.

§Analysed in 218 patients in the nintedanib group and 226 patients in the placebo group with cough at baseline, and 54 patients in the nintedanib group and 52 patients in the placebo group without cough at baseline. FVC, forced vital capacity; SGRQ, St George's Respiratory Questionnaire.

TABLE 4. Outcomes in subgroups by dyspnoea at baseline.

	Patients with dyspnoea		Patients without dyspnoea	
	Nintedanib (n=208)	Placebo (n=193)	Nintedanib (n=78)	Placebo (n=94)
Rate of decline in FVC (mL/year) over 52 weeks, adjusted mean (SE)	-70.1 (16.3)	-95.8 (16.5)	-7.9 (26.4)	-87.7 (23.9)
Difference (95% CI)	25.7 (-19.9, 71.3)		79.8 (9.8, 149.7)	
Treatment-by-time-by-subgroup interaction	p=0.20			
Relative decline in FVC (mL) >5% at week 52, n (%)	77 (37.0)	84 (43.5)	18 (23.1)	40 (42.6)
Odds ratio (95% CI)	0.76 (0.51, 1.13)		0.41 (0.21, 0.80)	
Treatment-by-subgroup interaction	p=0.13			
Relative decline in FVC (mL) >10% at week 52, n (%)	40 (19.2)	39 (20.2)	8 (10.3)	13 (13.8)
Odds ratio (95% CI)	0.93 (0.57, 1.52)		0.74 (0.29, 1.89)	
Treatment-by-subgroup interaction	p=0.67			
Absolute decline in FVC >5% predicted at week 52, n (%)	48 (23.1)	58 (30.1)	11 (14.1)	24 (25.5)

Odds ratio (95% CI)	0.69 (0.44, 1.07)		0.50 (0.23, 1.10)	
Treatment-by-subgroup interaction	p=0.49			
Absolute decline in FVC >10% predicted at week 52, n (%)	18 (8.7)	17 (8.8)	2 (2.6)	7 (7.4)
Odds ratio (95% CI)	0.99 (0.49, 1.99)		0.32 (0.06, 1.57)	
Treatment-by-subgroup interaction	p=0.20			
Absolute decline in FVC ≥10% predicted or death at week 52, n (%)	33 (15.8)*	47 (24.4)	7 (9.0)	15 (16.0)
Hazard ratio (95% CI)†	0.63 (0.40, 0.99)		0.48 (0.19, 1.20)	
Treatment-by-subgroup interaction	p=0.81			
Absolute change from baseline in SGRQ total score at week 52, adjusted mean (SE)‡	0.0 (1.1)	-0.7 (1.1)	2.9 (1.8)	-1.3 (1.6)
Difference (95% CI)	0.7 (-2.2, 3.6)		4.3 (-0.2, 8.8)	
Treatment-by-time-by-subgroup interaction	p=0.19			
Absolute increase from baseline in SGRQ total score of ≥4 points at week 52, n (%)§	77 (39.1)	63 (33.7)	34 (45.3)	30 (33.3)
Odds ratio (95% CI)	1.27 (0.84, 1.93)		1.63 (0.86, 3.07)	

Treatment-by-subgroup interaction	p=0.52
-----------------------------------	--------

*Analysed in 209 patients in the nintedanib group with dyspnoea at baseline. †Time-to-event analysis. ‡Analyzed in 206 patients in the nintedanib group and 190 patients in the placebo group with dyspnoea at baseline, and 76 patients in the nintedanib group and 92 patients in the placebo group without dyspnoea at baseline. §Analysed in 197 patients in the nintedanib group and 187 patients in the placebo group with dyspnoea at baseline, and 75 patients in the nintedanib group and 90 patients in the placebo group without dyspnoea at baseline. FVC, forced vital capacity; SGRQ, St George's Respiratory Questionnaire.